ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Regulation FD Disclosure

ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Regulation FD Disclosure
Item 7.01

On November 26, 2019, ANI Pharmaceuticals, Inc. (the “Company,” “we” or “us”) announced that Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development & Specialty Sales, and Mark Ginski, Vice President Cortrophin Product Development, will present at the Evercore ISI HealthCONx Conference in Boston, Massachusetts. The presentation will be webcast live at http://wsw.com/webcast/evercore4/anip/ at 10:15 AM ET on Tuesday, December 3, 2019. The live webcast will be archived and available for 90 days following the presentation.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

99.1 Press release, dated November 26, 2019, issued by ANI Pharmaceuticals, Inc.


ANI PHARMACEUTICALS INC Exhibit
EX-99.1 2 tm19238461_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference   BAUDETTE,…
To view the full exhibit click here

Story continues below

About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

An ad to help with our costs